Phase II Trial of Obinutuzumab Combinations in Relapsed/Refractory Follicular Lymphoma
A phase II trial is evaluating the efficacy of obinutuzumab with or without umbralisib, lenalidomide, or chemotherapy in patients with relapsed or refractory grade I-IIIa follicular lymphoma.
Phase II
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase II trial of obinutuzumab combinations could significantly influence treatment paradigms for relapsed or refractory follicular lymphoma. Monitoring the trial's outcomes is crucial for understanding potential shifts in clinical practice and competitive positioning in this evolving therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include trial results and any subsequent regulatory filings based on the findings.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.